← The Wire
SRPTNasdaq
Sarepta Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 873303
Sarepta Therapeutics develops and commercializes RNA-targeted therapies for rare genetic diseases
red 8-K · 90d
$1.62B
Market cap
$17.02
Last close
+1.0%
1D
-3.6%
5D
3.8M
Volume
Price · last 39 sessions-22.8%
May 4L $15.00 · H $23.03Jun 29
345
Total filings
Jun 4, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 4, 20268-KResults of OperationsMay 6, 202610-Q10-QMay 6, 2026DEFA14ADEFA14AApr 24, 2026DEF 14ADEF 14AApr 24, 202610-K10-KMar 2, 20268-KExecutive ChangeFeb 25, 20268-KResults of OperationsFeb 25, 20268-KResults of OperationsJan 12, 20268-KMaterial Agreement · New Debt / ObligationDec 19, 20258-KEquity Issuance · Company UpdateDec 11, 20258-KExecutive ChangeDec 8, 202510-Q10-QNov 6, 20258-KResults of OperationsNov 3, 20258-KMaterial Agreement · New Debt / ObligationAug 29, 20258-KEquity IssuanceAug 21, 20258-KExecutive ChangeAug 13, 202510-Q10-QAug 6, 20258-KCompany UpdateJul 21, 20258-KExecutive Change · Results of OperationsJul 16, 20258-KExecutive Change · Shareholder VoteJun 6, 202510-Q10-QMay 6, 2025DEFA14ADEFA14AApr 24, 2025DEF 14ADEF 14AApr 24, 202510-K10-KFeb 28, 20258-KResults of OperationsFeb 26, 20258-KMaterial Agreement · New Debt / ObligationFeb 14, 20258-KResults of OperationsJan 13, 20258-KMaterial AgreementNov 26, 202410-Q10-QNov 6, 20248-KExecutive Change · Bylaw AmendmentSep 16, 202410-Q10-QAug 7, 20248-KExecutive Change · Shareholder VoteJun 7, 202410-Q10-QMay 1, 2024DEF 14ADEF 14AApr 24, 2024DEFA14ADEFA14AApr 24, 202410-K10-KFeb 28, 2024SC 13GSEC SCHEDULE 13GFeb 9, 20248-KResults of Operations · Reg FD DisclosureJan 8, 202410-Q10-QNov 1, 202310-Q10-QAug 2, 20238-KReg FD DisclosureJun 22, 20238-KReg FD DisclosureJun 22, 20238-KExecutive Change · Shareholder VoteJun 9, 202310-Q10-QMay 2, 2023DEFA14ADEFA14AApr 24, 2023DEF 14ADEF 14AApr 24, 20238-KMaterial Agreement · Equity IssuanceMar 3, 202310-K10-KFeb 28, 20238-KResults of Operations · Reg FD DisclosureJan 9, 20238-KBylaw AmendmentDec 13, 20228-KExecutive ChangeNov 2, 202210-Q10-QNov 2, 20228-KMaterial Agreement · Agreement TerminatedSep 19, 202210-Q10-QAug 2, 20228-KExecutive Change · Shareholder VoteJun 3, 202210-Q10-QMay 4, 2022DEF 14ADEF 14AApr 25, 20228-KExecutive ChangeApr 21, 20228-KExecutive ChangeApr 5, 202210-K10-KMar 1, 2022SC 13GSC 13GFeb 14, 2022SC 13GJANUS HENDERSON GROUP PLC OWNS >5%Feb 11, 20228-KResults of Operations · Reg FD DisclosureJan 10, 20228-KExecutive ChangeNov 17, 202110-Q10-QNov 3, 20218-KMaterial Agreement · Results of OperationsOct 15, 2021424B5424B5Oct 15, 2021424B5424B5Oct 12, 20218-KReg FD DisclosureSep 27, 202110-QSRPT Q2 2021 10-QAug 4, 20218-KShareholder VoteJun 3, 20218-KReg FD DisclosureMay 18, 202110-QSRPT Q1 2021 10-QMay 5, 20218-KReg FD DisclosureMay 3, 2021DEFA14ADEFA14AApr 20, 2021DEF 14ADEF 14AApr 20, 202110-KSRPT 12/31/2020 10-KMar 1, 2021SC 13GSC 13GFeb 16, 2021SC 13GSEC SCHEDULE 13GFeb 10, 2021
Insider Activity
In the 90 days to Mar 12, 2026: 2 sold $417K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 12, 2026 | Mayo StephenDirector | Sell | 7,239 | $17.02 | $123K |
| Dec 16, 2025 | Estepan Ian MichaelChief Operating Officer | Sell | 13,187 | $22.31 | $294K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance